window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Phase 2 trial

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Protara reports durable 12-month responses for TARA-002 in Phase 2 bladder cancer trial

    Protara Therapeutics has reported updated 12-month data from its ongoing [...]

    May 19, 2026
  • Clinical & Regulatory,Therapeutic Areas

    Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial

    Kainova Therapeutics has dosed the first patient in Europe in [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Levicept reports Phase 2 osteoarthritis data in The Lancet showing pain reduction with LEVI-04

    Levicept has reported Phase 2 clinical trial results for LEVI-04 [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    SolasCure phase 2 trial shows faster healing in venous leg ulcers

    SolasCure has reported positive phase 2 data for Aurase Wound [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Sensei acquires Faeth and secures $200M to advance PIKTOR in endometrial and breast cancer

    Sensei Biotherapeutics has acquired Faeth Therapeutics and announced a concurrent [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Polaryx therapeutics selects contract research organization for SOTERIA phase 2 basket trial

    Polaryx Therapeutics, Inc has selected a leading contract research organization [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    ViiV Healthcare highlights ultra long-acting HIV pipeline and Phase 1 data at CROI 2026

    ViiV Healthcare will present new data from its long-acting and [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Alto Neuroscience completes Phase 2 enrollment for ALTO-101 in cognitive impairment associated with schizophrenia

    Alto Neuroscience has completed patient enrollment in its Phase 2 [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Boehringer Ingelheim’s apecotrep reduces proteinuria in Phase 2 FSGS trial

    Boehringer Ingelheim has reported Phase 2 clinical trial results showing [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Scancell clears FDA IND for iSCIB1+ registrational Phase 3 trial in advanced melanoma

    Scancell Holdings has announced that the U.S. Food and Drug [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Remepy and Merck KGaA partner on hybrid drug programmes
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Digital & Data, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • RxLogix launches AI pharmacovigilance platform for adverse event monitoring
    Categories: Clinical & Regulatory, Digital & Data, Drug Discovery & Development
  • Intellia reports first positive Phase 3 in vivo CRISPR data in hereditary angioedema
    Categories: Advanced Therapies, Clinical & Regulatory, Drug Discovery & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top